The relationship between plasma MMP-9 and TIMP-2 levels and intraocular pressure elevation in diabetic patients after intravitreal triamcinolone injection

Journal of Glaucoma

Volumn 17, Issue 4, 2008, Pages 253-256

  Yildirim, Nilgun ^a   Sahin, Afsun ^a   Erol, Nazmiye ^a   Kara, Selcuk ^a   Uslu, Sema ^a   Topbas, Seyhan ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Intraocular pressure; Intravitreal triamcinolone acetonide; MMP 9; TIMP 2

Indexed keywords

ANTIGLAUCOMA AGENT; GELATINASE B; HEMOGLOBIN A1C; KENACORT 40; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; GLUCOCORTICOID; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME BLOOD LEVEL; EYE EXAMINATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MALE; OCULOPLETHYSMOGRAPHY; OPHTHALMOSCOPY; PATHOGENESIS; PRESSURE MEASUREMENT; PRIORITY JOURNAL; SLIT LAMP; TREATMENT OUTCOME; VISUAL ACUITY; BLOOD; CHEMICALLY INDUCED DISORDER; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; INJECTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MIDDLE AGED; RETINA MACULA EDEMA; VITREOUS BODY;

ADULT; AGED; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OCULAR HYPERTENSION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TONOMETRY, OCULAR; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 47749131954     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31815c3a07     Document Type: Article

References (25)

1. Jonas JB, Hayler JK, Sofker A, et al. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2001;131:468-471.
2. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425-427.
3. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002; 109:920-927.
4. Lewis JM, Priddy T, Judd J, et al. Intraocular pressure response to topical dexamethasone as a predictor for the development of primary open-angle glaucoma. Am J Ophthalmol. 1988;106: 607-612.
5. Podos SM, Krupin T, Asseff C, et al. Topically administered corticosteroid preparations. Comparison of intraocular pressure effects. Arch Ophthalmol. 1971;86:251-254.
6. Rohen JW, Linner E, Witmer R. Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma. Exp Eye Res. 1973;17:19-31.
7. Becker B. Diabetes mellitus and primary open-angle glaucoma. The XXVII Edward Jackson Memorial Lecture. Am J Ophthalmol. 1971;1:1-16.
8. Gaston H, Absolon MJ, Thurtle OA, et al. Steroid responsiveness in connective tissue diseases. Br J Ophthalmol. 1983;67: 487-490.
9. Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163-167.
10. Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res. 1999;18:629-667.
11. Alexander JP, Samples JR, Van Buskirk EM, et al. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32:172-180.
12. Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, et al. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003;44:1117-1125.
13. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
14. el-Shabrawi Y, Eckhardt M, Berghold A, et al. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye. 2000;14(Pt 3A):375-383.
15. Samples JR, Alexander JP, Acott TS. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone. Invest Ophthalmol Vis Sci. 1993; 34:3386-3395.
16. Snyder RW, Stamer WD, Kramer TR, et al. Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. Exp Eye Res. 1993;57:461-468.
17. Ishizaki E, Takai S, Ueki M, et al. Correlation between angiotensinconverting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol. 2006;141:129-134.
18. Jin M, Kashiwagi K, Iizuka Y, et al. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina. 2001;21:28-33.
19. Kosano H, Okano T, Katsura Y, et al. ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci. 1999;64:2307-2315.
20. Noda K, Ishida S, Inoue M, et al. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2003;44:2163-2170.
21. Rosenblatt B, Benson W. Diabetic retinopathy. In: Yanoff M, Duker J, eds. Ophthalmology. St Louis: Mosby Inc; 2004:877-886.
22. Kon CH, Occleston NL, Charteris D, et al. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1998;39:1524-1529.
23. Matsuo T, Okada Y, Shiraga F, et al. TIMP-1 and TIMP-2 levels in vitreous and subretinal fluid. Jpn J Ophthalmol. 1998;42:377-380.
24. Becker B, Bresnick G, Chevrette L, et al. Intraocular pressure and its response to topical corticosteroids in diabetes. Arch Ophthalmol. 1966;76:477-483.
25. Fini ME, Girard MT. Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea. Invest Ophthalmol Vis Sci. 1990;31:1779-1788.